Effects of Liraglutide on Epicardial Fat Pro-Inflammatory Genes in Type 2 Diabetes and Coronary Artery Disease
Phase of Trial: Phase IV
Latest Information Update: 04 Oct 2018
At a glance
- Drugs Liraglutide (Primary)
- Indications Coronary artery disease; Type 2 diabetes mellitus
- Focus Pharmacodynamics; Pharmacogenomic
- 31 Aug 2018 Biomarkers information updated
- 09 Aug 2018 Status changed from not yet recruiting to recruiting.
- 03 Apr 2018 Planned End Date changed from 31 Dec 2019 to 30 Jun 2020.